Table 3 Knowledge gaps and research priorities.
From: Stealing nephrons—a review on how patent ductus arteriosus physiology impacts neonatal kidney health
Gap | Research Priority | |
|---|---|---|
How does a hemodynamically significant PDA, defined by composite measures indicating moderate to high volume shunting, influence rates of AKI in the NICU? | → | Investigate the relationship between PDA shunt volume and short/long term kidney outcomes. |
Can kidney dysfunction determine PDA management decisions? | → | Determine if new kidney biomarkers can detect nuances in PDA pathology and higher risk populations |
Does increased shunt exposure increase rates of AKI? CKD? | → | Correlate rates of AKI and CKD with duration of shunt exposure. |
Are different PDA treatment methods more protective against CKD development? | → | Determine if treating PDAs medically, procedurally, or both influence both short- and long-term kidney outcomes. |
Can biomarkers differentiate kidney dysfunction in neonates with hemodynamically significant PDAs? | → | Determine patterns in NIRS trends and other biomarkers in neonates with a PDA. |
Can biomarkers be used to predict treatment success or failure in neonates with hemodynamically significant PDAs? | → | Evaluate how NIRS and biomarkers change with PDA treatment. |
Can NIRS be used to stratify infants with hemodynamically significant PDAs at risk of short and long term kidney damage? | → | Determine whether a patterned change takes place in NIRS values in neonates with a PDA that varies with AKI stage. |
